AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Extracellular serine/threonine protein kinase FAM20C

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q8IXL6

UPID:

FA20C_HUMAN

Alternative names:

Dentin matrix protein 4; Golgi casein kinase; Golgi-enriched fraction casein kinase

Alternative UPACC:

Q8IXL6; A4D2Q5; L8B5W8; Q5I0W9; Q7Z4I0; Q9NPT2

Background:

Extracellular serine/threonine protein kinase FAM20C, also known as Dentin matrix protein 4, Golgi casein kinase, and Golgi-enriched fraction casein kinase, is pivotal in biomineralization of bones and teeth. It phosphorylates secretory pathway proteins within Ser-x-Glu/pSer motifs, contributing to the extracellular phosphoproteome. FAM20C's activity enhances ERO1A, crucial for endoplasmic reticulum redox homeostasis and oxidative protein folding. It also plays a role in osteoblast differentiation and mineralization.

Therapeutic significance:

Raine syndrome, an osteosclerotic bone dysplasia with neonatal lethal outcomes, is linked to variants affecting FAM20C. Understanding the role of Extracellular serine/threonine protein kinase FAM20C could open doors to potential therapeutic strategies for this and related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.